Introduction
Despite significant improvements in graft survival for kidney transplant recipients, 27% will experience graft loss within 5 years of transplant (1, 2) . Compared to those listed for primary kidney transplant, these patients have an increased risk of death on dialysis while awaiting retransplantation (re-KT) (3) . While survival benefits have been demonstrated for re-KT recipients, graft survival has been significantly worse compared to primary transplant recipients (4) (5) (6) . Re-KT candidates now comprise 14.3% of the waitlist, and it is anticipated that demand for re-KT will increase with growing acceptance of higher-risk recipients and increased utilization of marginal donors (1) .
Kidney transplantation is accepted as standard treatment for human immunodeficiency virus (HIV)-infected patients with end-stage renal disease (ESRD), who now comprise 1.5% of the US ESRD population (7) . Rates of comorbid diseases including diabetes, hypertension and hepatitis C (HCV) infection associated with ESRD in this population continue to rise, and it has been established that HIV-infected patients comprise a high-risk group for development of ESRD (8) (9) (10) (11) . Not surprisingly, studies have demonstrated that some subgroups of HIV-infected kidney transplant recipients are at increased risk of acute rejection and graft loss compared to their uninfected counterparts, particularly those coinfected with HCV (12) (13) (14) (15) . This increased risk for graft loss may contribute to an increasing pool of HIV-positive (HIV+) candidates needing re-KT.
As access to kidney transplant continues to expand for HIV+ candidates, it is expected that the demand for re-KT within this population will also increase, yet no study has explored the influence of HIV infection on patient outcomes among re-KT recipients. The goal of this study was to characterize the HIV+ re-KT population and explore patients' risk of mortality and graft loss in comparison to their uninfected counterparts.
Methods

Data source
This study utilized data from the Scientific Registry of Transplant Recipients (SRTR), which compiles data submitted by the members of the Organ Procurement and Transplantation Network (OPTN) on all donors, waitlisted candidates and transplant recipients in the United States. The Health Resources and Services Administration of the US Department of Health and Human Services provides oversight to the activities of the OPTN and SRTR contractors.
Study design
Adult re-KT recipients with known positive (n = 22) or negative (n = 4127) HIV status reported to the SRTR (2004-2013) were identified. The primary outcomes were patient and graft survival. Patient survival was defined as time from re-KT to death or administrative end of study. Graft survival was defined as time from re-KT to graft loss, return to dialysis or death and was censored for administrative end of study. Death data were supplemented by linkage to the Social Security Death Master File. Categorical donor and recipient characteristics were compared by HIV status using Fisher's exact test or chi-squared tests as appropriate, and continuous variables were compared with Wilcoxon rank-sum tests.
Survival analyses
Unadjusted survival time from re-KT was assessed using Kaplan-Meier curves and compared with the log-rank test. Risk factors for patient mortality and graft loss were identified using Cox proportional hazards with statistical significance set at p = 0.1. The final models examined risk by HIV status and adjusted for recipient age, race, HIV status, HCV status; donor age, race, and type; time between first graft loss and re-KT; and era of re- KT (2004 KT ( -2007 KT ( vs. 2008 KT ( -2013 . The proportional hazards assumption was assessed and verified using time-dependent covariates. A robust sandwich estimator was included to account for within-center clustering.
Interaction analysis
First-degree interaction terms between HIV status and re-KT were assessed on the multiplicative scale in a cohort of 115 614 adult, kidneyonly transplant recipients with known positive (n = 677) and negative (n = 114 937) HIV status reported to the SRTR (2004-2013) using multivariate Cox models. Additionally, modification of HIV infection by HCV infection among re-KT recipients was assessed in multivariate Cox models on the multiplicative scale through first-degree interaction terms.
Sensitivity analyses
HIV+ re-KT recipients were matched on recipient age, race, HCV status, kidney donor profile index (KDPI) and donor type to HIV-negative (HIVÀ) re-KT recipients in 1:3, 1:5 and 1:10 cohorts without replacement. Patient and graft survival were assessed in these three cohorts using Cox proportional hazards models. The results confirmed findings from the full multivariate models. The KDPI was calculated for all recipients of deceased donors, and living donor recipients were assigned a KDPI of 0. Additional models for patient and graft survival containing the KDPI as both a continuous and categorical variable were built. Inferences were similar to those obtained from the full multivariate models, which controlled for individual components of the KDPI (Table S1 ). For the purpose of simplicity, results from parsimonious models comparing patient and graft survival among HIV+ and HIVÀ re-KT recipients in the full cohort are presented.
Results
Patient and donor characteristics by HIV status
During the study period, there were 22 HIV+ re-KTs and 4127 HIVÀ re-KTs performed. Compared with HIVÀ re-KT recipients, HIV+ re-KT recipients were more commonly African American (63.6% vs. 26.7%, p < 0.001) and HCV-positive (HCV+) (31.8% vs. 5.0%, p < 0.001). HIV+ re-KT recipients were less likely to have private insurance compared to the general pool of HIVÀ re-KT recipients (9.1% vs. 31.6%, p = 0.02) and were more likely to have experienced delayed function of their first graft (63.6% vs. 26.2%, p = 0.004). Additionally, HIV+ patients were more frequently diagnosed with hypertension at the time of their first transplant in comparison to their uninfected counterparts (40.9% vs. 18.5%, p = 0.02). Time between transplants was comparable between HIV+ and HIVÀ re-KT recipients (1.5 years vs. 1.4 years, p = 0.52). There were no differences in the type of donor received at re-KT, with 27.3% of HIV+ recipients receiving a living donor compared to 30.0% of HIVÀ recipients (p = 0.78). Among deceased donors, utilization of KDPI > 85% grafts at the time of re-KT did not differ significantly by HIV status ( Table 1) .
Risk of graft loss after re-KT
In unadjusted survival analysis, HIV+ re-KT recipients had higher rates of graft loss compared to HIVÀ re-KT recipients (3 years: 33.3% vs. 17.3%, p = 0.01) ( Figure 1 ). After adjustment for relevant donor and recipient characteristics, HIV+ re-KT recipients continued to experience a 1.96-fold higher risk of graft loss compared to HIVÀ re-KT recipients (adjusted hazard ratio [aHR]: 1.96, 95% confidence interval [CI]: 1.14-3.36, p = 0.01) ( Table 2 ). The magnitude of this effect was increased 5.4-fold by the interaction between HIV and HCV coinfection (aHR: 5.40, 95% CI: 1.34-21.84, p = 0.02) ( Table 3) . While the joint effects of HIV infection and re-KT did confer a 1.6-fold increase in risk of graft loss compared to the risk associated with re-KT or HIV infection individually, the multiplicative interaction term did not reach statistical significance (aHR: 1.60, 95% CI: 0.80-3.21, p = 0.19) ( Table 4) .
Independent of HIV infection status, infection with HCV (aHR: 1.63, 95% CI: 1.34-1.99, p < 0.001) and utilization of grafts from African American donors (aHR: 1.26, 95% CI: 1.03-1.53, p = 0.03) were associated with increased risk of graft loss among re-KT recipients. Each year of waiting between loss of the primary kidney transplant (KT) and re-KT was associated with a 5% increased risk of graft loss (aHR: 1.05, 95% CI: 1.03-1.07, p < 0.001). Utilization of a living donor kidney for re-KT, however, was associated with a 37% reduction in the risk of graft loss (aHR: 0.63, 95% CI: 0.53-0.75, p < 0.001).
Transplantation in the modern era (2008-2013) was associated with a 21% reduction in the risk of graft loss (aHR: 0.79, 95% CI: 0.68-0.92, p = 0.0002) ( Table 2) .
Patient survival by HIV status
In unadjusted survival analysis, HIV infection was associated with higher rates of mortality after re-KT compared to re-KT in HIVÀ recipients (3 years: 19.8% vs. 7.9%, p = 0.003) (Figure 2 ). Among the seven HIV+ re-KT recipients who died during follow-up, five died with a functioning graft; three (42.9%) were infected with HCV; and five received a deceased-donor kidney at re-KT, of which two were KDPI > 85%. The median time between the primary transplant and the re-KT event was 1.9 years (interquartile range [IQR]: 0.7-6.4), and these patients survived a median 2.5 years (IQR: 0.9-4.3) following re-KT (Table 5) .
Following adjustment for donor and recipient characteristics, HIV+ re-KT recipients had a 3.11-fold increased risk of death compared to HIVÀ re-KT recipients (aHR: 3.11, 95% CI: 1.82-5.34, p < 0.001) ( Table 2 Independent of HIV infection status, infection with HCV (aHR: 1.77, 95% CI: 1.32-2.38, p = 0.001) and utilization of grafts from older donors (aHR: 1.01, 95% CI: 1.00-1.02, p = 0.001) were associated with increased risk of death among re-KT recipients. Moreover, for each year of waiting between the primary KT and re-KT, there was an associated 4% increased risk of death (aHR: 1.04, 95% CI: 1.01-1.07, p = 0.005). In contrast, re-KT from a living donor was associated with a 26% reduction in risk of death (aHR: 0.74, 95% CI: 0.60-0.92, p = 0.01), and transplantation in the modern era (2008-2013) was associated with a 17% reduction in risk of death (aHR: 0.83, 95% CI: 0.69-0.99, p = 0.04) ( Table 2 ). 
Discussion
In this study, we have compared the characteristics and patient and graft survival of 22 HIV+ re-KT recipients with 4127 HIVÀ re-KT recipients. We have shown that HIV+ re-KT candidates experienced similar waiting times between transplants as their HIVÀ re-KT counterparts, yet HIV+ re-KT recipients had a 3.11-fold increased risk of mortality and a 1.96-fold increased risk of graft loss after re-KT compared to their HIVÀ re-KT counterparts. While there were no significant differences in baseline characteristics with regard to donor type (e.g. living vs. deceased donor) at re-KT, HIV+ re-KT recipients were more commonly African American and infected with HCV compared to HIVÀ re-KT recipients. Moreover, coinfection with HCV magnified the effect of increased risk for graft loss 5.4-fold.
Despite increasing access to kidney transplantation for HIV+ patients, concerns about their outcomes compared to HIVÀ recipients remain, particularly among high-risk subgroups such as re-KT candidates (14, 16) . Increased mortality and suboptimal graft outcomes have been demonstrated among all re-KT recipients, regardless of HIV status (6) . Outcomes in the HIV+ re-KT population display similar trends, with inferior outcomes among re-KT recipients compared to those receiving their first kidney transplant (17) . When compared to HIVÀ re-KT recipients, however, HIV+ recipients had significantly worse graft and patient survival, although no significant interactions between HIV infection and re-KT were found.
Additionally, HCV infection continues to impart an increased risk of mortality and graft loss posttransplant, which is consistent with previous literature showing decreased graft and patient survival among HCV-infected recipients, regardless of HIV status (16) . Of particular concern, however, was the interaction identified between HIV and HCV infections, such that risk for graft loss was amplified 5.5-fold among HIV+ re-KT recipients in the presence of HCV coinfection. These findings provide some evidence that poor outcomes among HIV+ re-KT recipients may be driven by coinfection with HCV, necessitating consideration of HCV eradication in these patients (14, 16, 18) .
We also demonstrated that donor type and quality had significant impacts on outcomes following re-KT. Specifically, utilization of grafts from older donors increased the risk of mortality and graft loss following re-KT, independent of HIV status. This increased risk is consistent with earlier reports that re-KT with expanded criteria donors does not confer a survival benefit to re-KT candidates and suggests that low-quality grafts should be avoided in the re-KT setting, particularly for HIV+ candidates (19) . The impact of donor quality on patient survival was further illustrated by the high KDPI of grafts received by HIV+ re-KT recipients who died during follow-up. In contrast, utilization of allografts from living donors was associated with lower risk of death and graft loss after re-KT and may serve to mitigate the increased risk associated with re-KT.
Consistent with prior studies, waiting time between first graft failure and re-KT was found to be associated with increased risk of patient death and graft loss (20, 21) . While the time elapsed between transplants was similar between HIV+ and HIVÀ patients, HIV+ patients have been shown to experience increased risk of mortality on dialysis (22, 23) . This elevated risk may call for additional efforts to reduce waiting time for HIV+ re-KT candidates. Use of marginal deceased-donor kidneys (KDPI > 85%) may be considered in an attempt to minimize the time between transplants; however, given the increased risk of death and graft loss associated with grafts from older donors in re-KT recipients, such efforts may not be fruitful. Utilization of living donors was associated with decreased risk of death and graft loss, and approaches aimed at minimizing waiting time between graft loss and re-KT, possibly through the identification of living donors, could assist in improving patient outcomes in re-KT recipients, particularly among HIV+ candidates.
As with any analysis, there are limitations to this study. There are important recipient factors thought to influence HIV-infected patient outcomes, such as CD4 counts, viral loads and infections that are not captured in the SRTR; the impact of these factors upon patient survival in this population was thus not assessed. It is assumed, however, that most centers follow the recipient selection protocol set forth in the National Institutes of Health (NIH) multicenter study, which required undetectable viral loads and CD4 counts ≥ 200 for the waitlisting and transplantation of HIV-infected ESRD patients. Information on HIV viral escape, drug resistance, combination antiretroviral therapy (cART) regimen and immunosuppression changes was not available within the SRTR data; it is unknown to what extent HIV-specific measures may impact the risk of patient and graft loss in this patient population. Furthermore, the sample size of HIV+ re-KT recipients was small, which may impact the accuracy of our estimates. These data represent the totality of HIV+ re-KT patients in the United States and, as such, contribute novel and important information about patient outcomes in this population.
This is the first national study describing outcomes after re-KT among HIV+ recipients. We have shown that HIV infection at time of re-KT was associated with increased risk of death and graft loss compared to re-KT among HIVÀ recipients. Use of high KDPI grafts, increased time between first graft loss and subsequent re-KT, and recipient HCV infection were additional strong predictors of death and graft loss among re-KT recipients and should be avoided, particularly among HIV+ re-KT candidates.
